SG/CALL/BRISTOL-MYERS SQUIBB/65/0.1/21.03.25

SG/CALL/BRISTOL-MYERS SQUIBB/65/0.1/21.03.25 Stock

DE000SW7K7W0

Real-time Boerse Frankfurt Warrants 11:04:49 2024-06-26 EDT
0.027 ^EUR	+12.50%

Current month	-4.00%
1 month	+9.09%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/CALL/BRISTOL-MYERS SQUIBB/65/0.1/21.03.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	11:27am	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	11:08am	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	10:35am	MT
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	06-24	AQ

More news

Quotes 5-day view

Date	Price	Change
24-06-26	0.027	+12.50%
24-06-25	0.024	-7.69%
24-06-24	0.026	0.00%
24-06-21	0.026	+13.04%
24-06-20	0.023	+9.52%

Real-time Boerse Frankfurt Warrants

Last update June 26, 2024 at 11:04 am

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SW7K7W
ISIN	DE000SW7K7W0
Date issued	2024-03-12
Strike	65 $
Maturity	2025-03-21 (268 Days)
Parity	10 : 1
Emission price	0.18 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.2 €
Lowest since issue	0.018 €
Spread	0.01 €
Spread %	27.78%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company